Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer

Lung Cancer

Volumn 83, Issue 2, 2014, Pages 197-204

  Kaira, Kyoichi ^a   Serizawa, Masakuni ^a   Koh, Yasuhiro ^a   Takahashi, Toshiaki ^a   Yamaguchi, Aiko ^b   Hanaoka, Hirofumi ^b   Oriuchi, Noboru ^b   Endo, Masahiro ^a   Ohde, Yasuhisa ^a   Nakajima, Takashi ^a   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

18F FDG PET; GLUT1; Hypoxia; MTOR; NSCLC; PTEN

Indexed keywords

CARBOPLATIN; CD34 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HEXOKINASE 1; HYPOXIA INDUCIBLE FACTOR 1; PACLITAXEL; TEGAFUR; VASCULOTROPIN; EGFR PROTEIN, HUMAN; GLUCOSE; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; DRUG UPTAKE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; VERY ELDERLY; (18)F-FDG PET; HYPOXIA; LUNG TUMOR; METABOLISM; MTOR; NEOVASCULARIZATION (PATHOLOGY); NSCLC; PROGNOSIS; PTEN; SIGNAL TRANSDUCTION;

(18)F-FDG PET; GLUT1; HYPOXIA; MTOR; NSCLC; PTEN;

ANTIGENS, CD34; CARCINOMA, NON-SMALL-CELL LUNG; FLUORODEOXYGLUCOSE F18; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 3; HEXOKINASE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84892871930     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.11.025     Document Type: Article

References (26)

1. 18F]-fluoro-2-deoxy-d-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 2010, 28:3746-3753.
2. 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur J Cancer 2012, 48:1244-1254.
3. Vleugel M.M., Greijer A.E., Shvarts A., van der Groep P., van Berkel M., Aarbodem Y., et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1 alpha expression in invasive breast cancer. J Clin Pathol 2005, 58:172-177.
4. Elson D.A., Ryan H.E., Snow J.W., Johnson R., Arbeit J.M. Coordinate up-regulation of hypoxia inducible factor (HIF)-1a and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing 1. Cancer Res 2000, 60:6189-6195.
5. Ryan H.E., Polni M., McNulty W., Elson D., Gassmann M., Arbeit J.M., et al. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res 2000, 60:4010-4015.
6. Kaira K., Oriuchi N., Sunaga N., Ishizuka T., Shimizu K., Yamamoto N. A systemic review of PET and biology in lung cancer. Am J Transl Res 2011, 3:383-391.
7. 18F] FDG uptake in non-small cell lung cancer. Eur J Nucl Med 2000, 27:1778-1785.
8. 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT1 in non-small cell lung cancer. Eur J Cancer 2007, 43:1392-1398.
9. 18F-FDG uptake and prognosis impact in lung adenocarcinomas. J Nucl Med 2006, 47:419-425.
10. 18F-FDG uptake in non-small cell lung cancer. Cancer Sci 2009, 100:753-758.
11. 18FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everlimus. J Nucl Med 2009, 50:1815-1819.
12. Cejka D., Kuntner C., Preusser M., Fritzer-Szekeres M., Fueger B.J., Strommer S., et al. FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo. Br J Cancer 2009, 100:1739-1745.
13. 18F]Fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol 2009, 27:2697-2704.
14. Mountain C.F. Revision in the international system for staging lung cancer. Chest 1997, 11:1710-1717.
15. 2-adrenoceptors on glycogenolysis. Neuropsychopharmacology 2008, 33:2384-2397.
16. Hayashi M., Sakata M., Takeda T., Yamamoto T., Okamoto Y., Sawada K., et al. Induction of glucose transporter 1 expression through hypoxia-inducible factor 1α under hypoxic conditions in trophoblast-derived cells. J Endocrinol 2004, 183:145-154.
17. Vissers M.C., Gunningham S.P., Morrison M.J., Dachs G.U., Currie M.J. Modulation of hypoxia-inducible factor-1 alpha in cultured primary cells by intracellular ascorbate. Free Radic Biol Med 2007, 42:765-772.
18. Mosmann T. Rapid calorimetric assay for cellular growth and survival: application of proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
19. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J Nucl Med 2009, 50:1770-1776.
20. 18F] fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005, 23:1136-1143.
21. 18F-fluoro-2-deoxy-glucose-positron emission tomography in non-small cell lung cancer: an analysis of 125 cases. J Clin Oncol 1999, 17:3201-3206.
22. 11C-methionine for the detection of hilar and mediastinal lymph node metastasis in lung cancer. J Nucl Med 2000, 41:283-290.
23. Nomori H., Watanabe K., Ohtsuka T., Naruke T., Suemasu K., Uno K. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3cm in diameter, with special reference to the CT images. Lung Cancer 2004, 45:19-27.
24. Sagawa M., Higashi K., Sugita M., Ueda Y., Maeda S., Toga H., et al. Fluorodeoxyglucose uptake correlates with the growth pattern of small peripheral pulmonary adenocarcinoma. Surg Today 2006, 36:230-234.
25. Carins R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat Rev Cancer 2011, 11:85-95.
26. Morani F., Pagano L., Prodam F., Aimaretti G., Isidoro C. Loss of expression of the oncosuppressor PTEN in thyroid incidentalomas associates with GLUT1 plasmamembrane expression. Panminerva Med 2012, 54:59-63.